belinostat (Beleodaq)

From Aaushi

Jump to navigation Jump to search

^[1]^[2]

Indications

refractory peripheral T-cell lymphoma^[1]

Adverse effects

Mechanism of action

inhibits histone deacetylase^[2]

More general terms

References

↑ ^1.0 ^1.1 FDA News Release. July 3, 2014 FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm
↑ ^2.0 ^2.1 PubChem: 6918638

Database

PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6918638

Retrieved from "https://aaushi.info/w/index.php?title=A441988&oldid=932562"

↑ Back to top